BioNTech successfully met the minimum condition for its exchange offer to acquire CureVac, with 81.74% of CureVac shares tendered. The subsequent offering period will continue until December 18, 2025, allowing remaining shareholders to participate.

BioNTech reported Q2 sales of $295.7 million, exceeding expectations, with a narrowed per-share loss. The company strengthened its oncology strategy through a collaboration with Bristol Myers Squibb and plans to acquire CureVac.

The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.

Halper Sadeh LLC, an investor rights law firm, is investigating several companies for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.

While smaller deals have been completed, including overseas acquisitions, the expected surge in large-scale mergers and acquisitions has not materialized. Factors like trade policy uncertainty and economic concerns have kept corporate decision-makers cautious about striking major deals.